Показано 0 из 0
Дата |
---|
18:42 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
2.37
|
2.40
|
2.03
|
2.0201
|
2.48
|
2.37
|
|
|
1 300 051.56
|
2 148.00
|
1.96
|
2.01
|
2.11
|
1.90
|
2.12
|
1.96
|
|
|
256 854.82
|
617.00
|
2.09
|
2.15
|
1.99
|
1.97
|
2.1799
|
2.12
|
|
|
230 907.55
|
552.00
|
1.85
|
1.93
|
2.13
|
1.96
|
2.1379
|
1.98
|
|
|
334 578.14
|
861.00
|
2.05
|
2.07
|
2.20
|
2.12
|
2.30
|
2.13
|
|
|
353 912.44
|
988.00
|
2.21
|
2.27
|
2.30
|
2.12
|
2.34
|
2.20
|
|
|
252 216.27
|
994.00
|
2.20
|
2.28
|
2.30
|
2.11
|
2.46
|
2.32
|
|
|
938 564.00
|
2 194.00
|
2.27
|
2.39
|
2.05
|
2.01
|
2.33
|
2.28
|
|
|
370 521.84
|
879.00
|
2.04
|
2.07
|
1.87
|
1.87
|
2.07
|
2.04
|
|
|
315 781.81
|
674.00
|
1.90
|
2.01
|
2.00
|
1.89
|
2.0445
|
1.92
|
|
|
166 126.16
|
476.00
|
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.